CVRx Earnings Call: Investing Heavily for Future Growth

Cvrx, Inc. ((CVRX)) has held its Q4 earnings call. Read on for the main highlights of the call.

CVRx’s latest earnings call blended notable strategic wins with ongoing financial strain and modest near-term growth. Management struck an optimistic tone around reimbursement breakthroughs, margin expansion and a pivotal heart failure trial, while openly acknowledging persistent net losses, rising operating expenses and continued cash burn as the commercial engine scales.

Quarter and Full-Year Revenue

CVRx reported fourth-quarter revenue of $16.0 million, a 4% year-over-year increase of $0.7 million. Full-year 2025 revenue reached $56.7 million, as executives framed 2025 as a heavy investment year aimed at building a larger, more durable commercial franchise rather than maximizing short-term earnings.

U.S. Volume and Revenue Growth

U.S. revenue in the quarter climbed to $14.9 million, up 4% or $0.6 million from a year earlier. Implant volumes showed more robust momentum than dollars, with U.S. revenue units rising 18% to 478 from 404, indicating underlying procedural growth that pricing and mix did not fully translate into headline sales.

Improved Profitability Metrics

Profitability metrics moved in the right direction even as the company invests. Fourth-quarter gross profit rose 8% year-over-year to $13.8 million and gross margin expanded to 86% from 83%, helped by a U.S. average selling price now assumed above $31,000 and manufacturing efficiencies that lowered unit costs.

Commercial Footprint Expansion and Deep-Account Performance

The commercial footprint continued to widen, with the sales organization growing to 53 territories, about 10% higher than year-end 2024. Active implanting centers increased to 252, up 13%, and the top 20% of sites averaged an annualized rate of roughly 19 implants in the quarter, versus an estimated 300 eligible patients per top center, suggesting significant penetration headroom.

Reimbursement Milestone — Category I CPT Code

A key highlight was the transition to Category I CPT codes effective early 2026, a structural shift for reimbursement. Management expects the move to eliminate automatic denials tied to Category III codes, standardize physician payment near $560 nationally and reduce friction for patients and physicians over the coming quarters.

Improved Prior Authorization Outcomes

Even ahead of the Category I change, access metrics improved meaningfully. The 30-day Medicare Advantage prior authorization approval rate reached 46% in 2025, up from 31% in 2024, and management framed this 15-point jump as evidence that payer education and process work are beginning to ease bottlenecks in patient access.

BENEFIT HF — Landmark Randomized Trial Initiated

The company initiated the BENEFIT HF randomized trial under CMS Category B coverage, enrolling 2,500 patients across about 100 centers in the U.S. and Germany. If the trial shows benefits in mortality and heart failure decompensation, the eligible population could nearly triple from roughly 339,000 to about 980,000 patients, implying a potential addressable market near $30 billion over time.

Strengthened Liquidity and Debt Flexibility

Liquidity remains solid with $75.7 million in cash and equivalents at year-end and an amended term loan facility that can reach up to $100 million. CVRx drew an additional $10 million in January, bringing outstanding principal to $60 million, and views the remaining capacity as a source of nondilutive capital that provides at least two years of operating runway.

Medical Education and Program Development

To deepen adoption, CVRx executed more than 150 educational events in 2025 across local, regional and national levels. The company also leaned into a program-selling model, concentrating on prioritized accounts, training teams and refreshing field leadership to build lasting referral networks and institutional workflows around Barostim therapy.

Wider Net Loss

Despite revenue and margin gains, losses widened as investments ramped. Net loss for 2025 increased to $11.9 million from $10.7 million, or $0.46 per share versus $0.43, with management emphasizing that higher spending is deliberate and tied to long-term growth initiatives rather than short-term cost control.

High Operating Expenses and Aggressive SG&A

Operating expenses, particularly SG&A, are climbing as the company scales its commercial infrastructure. Fourth-quarter SG&A rose 9% year-over-year to $22.0 million on higher compensation, advertising and travel, and guidance for 2026 operating expenses of $103–107 million signals continued aggressive investment that will weigh on near-term profitability.

Cash Burn and Trial Cash Impact

Management expects 2026 cash usage of roughly $30–35 million, underscoring that CVRx will remain a cash-burning story for now. The BENEFIT HF trial is projected to have a net cash impact of $20–30 million spread over five to seven years, with heavier spending in later periods, adding to outflows even as the company underscores its strong liquidity buffer.

Modest Near-Term Revenue Growth and Sales Ramp Effects

Near-term revenue growth remained modest, with the quarter up just 4% year-over-year, as the larger sales force is still ramping. Management noted that integrating many new representatives created short-term friction and some accounts were sunsetting while new ones came online, muting sequential account expansion and activation in certain periods.

Non-Operating Income Decline and Increased Leverage

Below the operating line, non-operating trends were less favorable, with other income falling to $0.7 million from $1.1 million, a roughly 36% decline. At the same time, term loan principal increased to $60 million and future access to the remaining facility is contingent on milestones, leaving CVRx more leveraged and reliant on continued debt availability.

Delayed Financial Contribution from Major Initiatives

Management cautioned that major strategic projects will take time to translate into the income statement. The BENEFIT HF trial is not expected to materially lift 2026 revenue, and the benefit of Category I CPT codes will roll in gradually as payers update systems and prior authorization processes, delaying the full financial payoff from these initiatives.

Guidance and Outlook

For 2026, CVRx guided revenue to $63.0–67.0 million, implying about 11–18% growth over 2025, with gross margin expected between 84% and 86%. The company plans to add roughly three territories per quarter, target high-single-digit quarterly account growth, operate with an assumed U.S. ASP of about $31,000 and manage within a projected cash burn of $30–35 million while maintaining around $86 million of starting liquidity and access to additional term loan capital.

CVRx’s call painted a picture of a company trading near-term earnings for long-term strategic position, with reimbursement gains, clinical expansion and high margins all supporting a bullish multi-year thesis. For investors, the story now hinges on sustained procedure growth, careful cash management and successful execution of BENEFIT HF, as the financial benefits of today’s investments emerge over the next several years.